Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

On or about September 15, 2023, Neumora conducted the IPO and raised more than $250 million from the investing public. The lawsuit alleges that, unbeknownst to investors, Neumora's KOASTAL-1 study, ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

TD Cowen 45th Annual Health Care Conference on March 4 in Boston Leerink Partners Global Biopharma Conference on March 12 in Mia ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by ...